Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Roula Albadine"'
Publikováno v:
Endocrine Oncology, Vol 3, Iss 1, Pp 1-7 (2023)
Ectopic adrenocorticotrophic hormone (ACTH) secretion (EAS) is a rare cause of ACTH-dependent Cushing’s syndrome (CS), most often caused by a thoracic neuroendocrine tumor (NET). Large-cell neuroendocrine carcinomas (LCNEC) with EAS are rare and us
Externí odkaz:
https://doaj.org/article/b45f18e404ee4d65ac659e7fff72ebca
Autor:
Camille Gauvin, Vimal Krishnan, Imane Kaci, Danh Tran-Thanh, Karine Bédard, Roula Albadine, Charles Leduc, Louis Gaboury, Normand Blais, Mustapha Tehfe, Bertrand Routy, Marie Florescu
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 593-605 (2021)
Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as ant
Externí odkaz:
https://doaj.org/article/b7d1f78fea3d40e9b7d385488bc5592c
Autor:
Vincent Q. Trinh, Nazim Benzerdjeb, Ségolène Chagnon-Monarque, Nicolas Dionne, Guila Delouya, André Kougioumoutzakis, Jennifer Sirois, Roula Albadine, Mathieu Latour, Anne-Marie Mes-Masson, Hélène Hovington, Alain Bergeron, Kevin C. Zorn, Yves Fradet, Fred Saad, Daniel Taussky, Dominique Trudel
Publikováno v:
Radiation Oncology, Vol 14, Iss 1, Pp 1-10 (2019)
Abstract Background Intraductal carcinoma of the prostate (IDC-P) is an independent biomarker of recurrence and survival with particular treatment response, yet no study has tested its response to radiotherapy. The aim of our project was to test the
Externí odkaz:
https://doaj.org/article/99a668a744c641e5b96067b06bed853e
Autor:
Mame-Kany Diop, Roula Albadine, André Kougioumoutzakis, Nathalie Delvoye, Hélène Hovington, Alain Bergeron, Yves Fradet, Fred Saad, Dominique Trudel
Publikováno v:
Cancers, Vol 13, Iss 24, p 6243 (2021)
Intraductal carcinoma of the prostate (IDC-P) is an aggressive subtype of prostate cancer strongly associated with an increased risk of biochemical recurrence (BCR). However, approximately 40% of men with IDC-P remain BCR-free five years after radica
Externí odkaz:
https://doaj.org/article/37f97b1247b446ce8d84b647ff9e4abb
Autor:
Andrée-Anne Grosset, Frédérick Dallaire, Tien Nguyen, Mirela Birlea, Jahg Wong, François Daoust, Noémi Roy, André Kougioumoutzakis, Feryel Azzi, Kelly Aubertin, Samuel Kadoury, Mathieu Latour, Roula Albadine, Susan Prendeville, Paul Boutros, Michael Fraser, Rob G Bristow, Theodorus van der Kwast, Michèle Orain, Hervé Brisson, Nazim Benzerdjeb, Hélène Hovington, Alain Bergeron, Yves Fradet, Bernard Têtu, Fred Saad, Frédéric Leblond, Dominique Trudel
Publikováno v:
PLoS Medicine, Vol 17, Iss 8, p e1003281 (2020)
BACKGROUND:Prostate cancer (PC) is the most frequently diagnosed cancer in North American men. Pathologists are in critical need of accurate biomarkers to characterize PC, particularly to confirm the presence of intraductal carcinoma of the prostate
Externí odkaz:
https://doaj.org/article/8fcceac90c674478ae01e4c367277d85
Autor:
Helen Pantazopoulos, Afnan Al-Saleh, Mame Kany Diop, David Boucher Roy, Roy Nitulescu, Roula Albadine, Dominique Trudel
Publikováno v:
Journal of Urology. 209
Autor:
Michael A. Carducci, Angelo M. De Marzo, Robin Gurganus, Daniel J. George, Phillip G. Febbo, Helen Fedor, Antonio Jimeno, Alan W. Partin, Luciana Schultz, Roula Albadine, Ting Wang, S. Lindsay Davis, Kelly Mundy, Patricia A. Creel, David P. Wood, Susan Halabi, Michelle A. Rudek, George J. Netto, Andrew J. Armstrong
Purpose: Given discrepancies between preclinical and clinical observations of mammalian target of rapamycin (mTOR) inhibition in prostate cancer, we sought to determine the pharmacodynamic effects of the mTOR/TORC1 inhibitor rapamycin in men with int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d89e2c593bd06ba355c5eb1dd80c5a7
https://doi.org/10.1158/1078-0432.c.6519354
https://doi.org/10.1158/1078-0432.c.6519354
Autor:
Michael A. Carducci, Angelo M. De Marzo, Robin Gurganus, Daniel J. George, Phillip G. Febbo, Helen Fedor, Antonio Jimeno, Alan W. Partin, Luciana Schultz, Roula Albadine, Ting Wang, S. Lindsay Davis, Kelly Mundy, Patricia A. Creel, David P. Wood, Susan Halabi, Michelle A. Rudek, George J. Netto, Andrew J. Armstrong
Supplementary Data from A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b5a4fa2460be48a93fb41a6b517b0c3
https://doi.org/10.1158/1078-0432.22442682.v1
https://doi.org/10.1158/1078-0432.22442682.v1
Autor:
Tracy Tucker, Margaret M. Kelly, Jean-Claude Cutz, Ming-Sound Tsao, Ranjit Waghray, Weei-Yuan Huang, Doha Itani, Christian Couture, Adam C. Smith, Carol C. Cheung, Fariboz Rashid-Kolvear, Emina Torlakovic, Yasushi Yatabe, Anna Bojarski, Michel R. Nasr, Aly Karsan, Zhaolin Xu, Gefei Qing, Iyare Izevbaye, Roula Albadine, Gilbert Bigras, Harmanjatinder S. Sekhon, Joan H.M. Knoll, Alan Spatz, H. Wang, Keith Kwan, Diana N. Ionescu, Tracy Stockley, Danh Tran-Thanh
Publikováno v:
Lung Cancer. 160:127-135
Patients with non-small cell lung cancer (NSCLC) harboring ROS proto-oncogene 1 (ROS1) gene rearrangements show dramatic response to the tyrosine kinase inhibitor (TKI) crizotinib. Current best practice guidelines recommend that all advanced stage no
Autor:
Roula Albadine, Danh Tran-Thanh, Charles Leduc, Mustapha Tehfe, Vimal Krishnan, Normand Blais, Bertrand Routy, Louis Gaboury, Imane Kaci, Karine Bédard, Marie Florescu, Camille Gauvin
Publikováno v:
Current Oncology, Vol 28, Iss 59, Pp 593-605 (2021)
Current Oncology
Volume 28
Issue 1
Pages 59-605
Current Oncology
Volume 28
Issue 1
Pages 59-605
Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as ant